Morningstar - Natwest Group (NWG) RBS Starts 2018 Well; While Results Are Somewhat Encouraging, Litigation Remains as Downside Risk

Report

Morningstar

Derya Guzel

EUR 100.00 For Business Accounts Only

RBS Starts 2018 Well; While Results Are Somewhat Encouraging, Litigation Remains as Downside Risk

Royal Bank of Scotland booked GBP 792 million attributable profit for the first quarter, more than triple its GBP 259 million in the year-ago quarter. RBSâ€™ total revenue line increased 3% during the quarter, supported by an 18% increase in non-interest-income-related items, while net interest income saw a 4% decline year over year. Within the revenue-generating items, RBS kept fees flat as trading income increased 4%.Â
A boost in the bottom line mainly came from the cost line through a sharp dec...

27/04/2018 15 EN

Underlying

Natwest Group

See profile

US7800976893 New York Stock Exchange United Kingdom

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Derya Guzel

Other Reports on these Companies

Edison Investment Research

NatWest Group - Time for a re-rating?

Q423 earnings demonstrated the inherent profitability and resilience of returns at NatWest Group (NWG). PBT came in 25% ahead of consensus, with beats on both revenues and impairments along with good cost control. Despite continuing normalisation of credit and assuming around two more base rate cuts in 2024 than are currently priced into the bond market, management expects to deliver a return on tangible equity (RoTE) of c 12%. On consensus estimates, the shares trade at 0.8x tangible net asset value (TNAV) and P/E of 6.4x in 2024e. Without a re-rating, the consensus 10% TNAV growth and 6.4% y...

March 5, 2024 March 5, 2024 1 EN

Morningstar

Morningstar | Business Uncertainty Following Prolonged Brexit Hangs Over RBS' Near-Term Income Outlook

RBS reported first-quarter 2019 operating profit before tax of GBP 1 billion compared with GBP 1.2 billion the same period a year ago. Lower operating expenses, down nearly 4% year over year, were not enough to offset weaker income generation. Net interest income declined 5% to GBP 2 billion, mostly driven by NatWest markets and personal banking. Excluding one-off items in these segments, generally higher economic uncertainty and continuously high competition in the mortgage market could be seen as the underlying factors driving this performance. The Brexit delays and accompanying business unc...

EUR 850.00

April 29, 2019 April 29, 2019 3 EN

Morningstar

Morningstar | New RBS Company Report

While there are signs of green shoots in Royal Bank of Scotland's revenue generation, challenges regarding litigation and restructuring costs, as well as revenue generation, remain to be dealt with in the short term. RBS posted 2018 full-year annual net income of GBP 1.6 billion versus GBP 752 million in 2017. While operationally somewhat better than the previous year, significantly lower restructuring costs were the biggest supportive factor in 2018. Although it is rather slower than peers, it seems RBS' management has found a good path to resolve outstanding issues and to operationally catch...

EUR 850.00

April 29, 2019 April 29, 2019 3 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

RBS Starts 2018 Well; While Results Are Somewhat Encouraging, Litigation Remains as Downside Risk

NatWest Group - Time for a re-rating?

Morningstar | Business Uncertainty Following Prolonged Brexit Hangs Over RBS' Near-Term Income Outlook

Morningstar | New RBS Company Report

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe